| C039775 | 10,11-dihydro-10-hydroxycarbamazepine | "10,11-dihydro-10-hydroxycarbamazepine results in decreased activity of CYP2C19 protein" | 17516704 |
| C495657 | 1,1,1-trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane | "CYP2C19 protein results in increased chemical synthesis of 1,1,1-trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane" | 9714305|9733665 |
| C495657 | 1,1,1-trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane | "CYP2C19 protein results in increased hydroxylation of 1,1,1-trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane" | 9714305 |
| C517214 | 12-hydroxyellipticine | CYP2C19 protein results in increased chemical synthesis of 12-hydroxyellipticine | 22917556 |
| C585955 | 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid | Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] | 24120545 |
| C585955 | 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid | [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid | 24120545 |
| C585955 | 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid | Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] | 24120545 |
| C585955 | 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid | Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] | 24120545 |
| C585955 | 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid | Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] | 24120545 |
| C053854 | 1,3,8-trihydroxy-6-hydroxymethylanthraquinone | "CYP2C19 protein results in increased chemical synthesis of 1,3,8-trihydroxy-6-hydroxymethylanthraquinone" | 27989148 |
| C517215 | 13-hydroxyellipticine | CYP2C19 protein results in increased chemical synthesis of 13-hydroxyellipticine | 22917556 |
| C090768 | 1-(4-hydroxyphenyl)-1,2-diphenyl-1-butene | "CYP2C19 protein results in increased abundance of 1-(4-hydroxyphenyl)-1,2-diphenyl-1-butene" | 29285606 |
| C090768 | 1-(4-hydroxyphenyl)-1,2-diphenyl-1-butene | "CYP2C19 protein results in increased metabolism of 1-(4-hydroxyphenyl)-1,2-diphenyl-1-butene" | 29285606 |
| C090768 | 1-(4-hydroxyphenyl)-1,2-diphenyl-1-butene | "[CYP2C19 protein results in increased metabolism of 1-(4-hydroxyphenyl)-1,2-diphenyl-1-butene] which results in increased abundance of 1-(4-hydroxyphenyl)-1,2-diphenyl-1-butene metabolite" | 29285606 |
| C090768 | 1-(4-hydroxyphenyl)-1,2-diphenyl-1-butene | "[CYP2C19 protein results in increased metabolism of Tamoxifen] which results in increased abundance of 1-(4-hydroxyphenyl)-1,2-diphenyl-1-butene" | 29285606 |
| C035342 | 1,4-naphthoquinone | "CYP2C19 protein results in increased abundance of 1,4-naphthoquinone" | 16243959 |
| C558737 | 1-(6-((2-(dimethylamino)ethyl)(methyl)amino)-1,3-dimethyl-1H-pyrazolo(3,4-b)pyridine-5-carbonyl)-3-(3-isopropoxyphenyl)urea | "1-(6-((2-(dimethylamino)ethyl)(methyl)amino)-1,3-dimethyl-1H-pyrazolo(3,4-b)pyridine-5-carbonyl)-3-(3-isopropoxyphenyl)urea affects the activity of CYP2C19 protein" | 21341682 |
| C486136 | 16-O-demethylaconitine | [Omeprazole results in decreased activity of CYP2C19 protein] which results in decreased chemical synthesis of 16-O-demethylaconitine metabolite | 21277363 |
| C029350 | 1-naphthol | CYP2C19 protein results in increased abundance of 1-naphthol | 16243959 |
| C024336 | 1-phenylazo-2-naphthol | CYB5A protein inhibits the reaction [CYP2C19 protein results in increased oxidation of 1-phenylazo-2-naphthol] | 17159775 |
| C024336 | 1-phenylazo-2-naphthol | CYP2C19 protein results in increased oxidation of 1-phenylazo-2-naphthol | 17159775 |
| C054919 | 2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene | "2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene results in decreased activity of CYP2C19 protein" | 25542188 |
| C054917 | 2,2-(2-chlorophenyl-4'-chlorophenyl)acetic acid | "2,2-(2-chlorophenyl-4'-chlorophenyl)acetic acid results in decreased activity of CYP2C19 protein" | 25542188 |
| C067411 | 2,2-dichloro-1,1,1-trifluoroethane | "CYP2C19 protein results in increased metabolism of 2,2-dichloro-1,1,1-trifluoroethane" | 11684365 |
| C077584 | 2-amino-1-methyl-6-(4-hydroxyphenyl)imidazo(4,5-b)pyridine | "[CYP2C19 protein results in increased metabolism of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased chemical synthesis of 2-amino-1-methyl-6-(4-hydroxyphenyl)imidazo(4,5-b)pyridine" | 17279779 |
| C049584 | 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine | "CYP2C19 protein results in increased metabolism of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine" | 17279779 |
| C049584 | 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine | "[CYP2C19 protein results in increased metabolism of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased chemical synthesis of 2-amino-1-methyl-6-(4-hydroxyphenyl)imidazo(4,5-b)pyridine" | 17279779 |
| C049584 | 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine | "[CYP2C19 protein results in increased metabolism of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased chemical synthesis of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine" | 17279779 |
| C586542 | 2'-(glutathion-S-yl)-deschlorodiclofenac | [CYP2C19 protein co-treated with GSTP1 protein co-treated with Glutathione] results in increased abundance of 2'-(glutathion-S-yl)-deschlorodiclofenac | 24246759 |
| C060533 | 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine | "[CYP2C19 protein results in increased metabolism of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased chemical synthesis of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine" | 17279779 |
| C005328 | 2-nitroanisole | CYP2C19 protein results in increased oxidation of 2-nitroanisole | 21218109 |
| C540904 | 2-oxo-clopidogrel | CYP2C19 protein results in increased oxidation of 2-oxo-clopidogrel | 19812348 |
| C540904 | 2-oxo-clopidogrel | N-3-benzylnirvanol inhibits the reaction [CYP2C19 protein results in increased oxidation of 2-oxo-clopidogrel] | 19812348 |
| C540904 | 2-oxo-clopidogrel | Omeprazole inhibits the reaction [CYP2C19 protein results in increased oxidation of 2-oxo-clopidogrel] | 19812348 |
| C018855 | 2-tert-butylhydroquinone | 2-tert-butylhydroquinone results in increased expression of CYP2C19 mRNA | 24830941 |
| C018855 | 2-tert-butylhydroquinone | 2-tert-butylhydroquinone results in increased expression of CYP2C19 protein | 24830941 |
| C109602 | 3-(2-(4-(3-chloro-2-methylphenyl)1-piperazinyl)ethyl)5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazol dihydrochloride 3.5 hydrate | "3-(2-(4-(3-chloro-2-methylphenyl)1-piperazinyl)ethyl)5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazol dihydrochloride 3.5 hydrate results in decreased activity of CYP2C19 protein" | 16049129 |
| C109602 | 3-(2-(4-(3-chloro-2-methylphenyl)1-piperazinyl)ethyl)5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazol dihydrochloride 3.5 hydrate | "CYP2C19 protein affects the metabolism of 3-(2-(4-(3-chloro-2-methylphenyl)1-piperazinyl)ethyl)5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazol dihydrochloride 3.5 hydrate" | 16049129 |
| C023035 | 3,4,5,3',4'-pentachlorobiphenyl | "3,4,5,3',4'-pentachlorobiphenyl results in increased expression of CYP2C19 mRNA" | 19692669 |
| C012587 | 3,5,6-trichloro-2-pyridinol | "CYP2C19 protein results in increased chemical synthesis of 3,5,6-trichloro-2-pyridinol" | 22281205 |
| C016834 | 3,5-xylenol | "CYP2C19 protein results in increased oxidation of 3,5-xylenol analog" | 27665777 |
| C016834 | 3,5-xylenol | "[CYP2C19 protein results in increased oxidation of 3,5-xylenol analog] which results in increased abundance of 4-(methylsulfinyl)phenol analog" | 27665777 |
| C571631 | 3-bromomethcathinone | CYP2C19 protein results in increased metabolism of 3-bromomethcathinone | 27320963 |
| C064809 | 3-phenoxybenzylalcohol | CYP2C19 protein results in increased abundance of 3-phenoxybenzylalcohol | 24548679 |
| C008745 | 4,4'-bisphenol F | "CYP2C19 protein results in increased glutathionylation of 4,4'-bisphenol F" | 23470418 |
| C008745 | 4,4'-bisphenol F | "CYP2C19 protein results in increased glutathionylation of 4,4'-bisphenol F metabolite" | 23470418 |
| C008745 | 4,4'-bisphenol F | "CYP2C19 protein results in increased hydroxylation of 4,4'-bisphenol F" | 23470418 |
| C570106 | 4,4'-cyclohexylidenebisphenol | "CYP2C19 protein results in increased glutathionylation of 4,4'-cyclohexylidenebisphenol" | 23470418 |
| C570106 | 4,4'-cyclohexylidenebisphenol | "CYP2C19 protein results in increased glutathionylation of 4,4'-cyclohexylidenebisphenol metabolite" | 23470418 |
| C570106 | 4,4'-cyclohexylidenebisphenol | "CYP2C19 protein results in increased hydroxylation of 4,4'-cyclohexylidenebisphenol" | 23470418 |
| C583074 | 4,4'-hexafluorisopropylidene diphenol | "CYP2C19 protein results in increased hydroxylation of 4,4'-hexafluorisopropylidene diphenol" | 23470418 |
| C545880 | 4,5-dihydropyrazole-1,5-dicarboxylic acid 1-((4-chlorophenyl)-amide) 5-(2-oxo-2H-(1,3')bipyridinyl-6'-yl)-amide | "CYP2C19 protein results in increased metabolism of 4,5-dihydropyrazole-1,5-dicarboxylic acid 1-((4-chlorophenyl)-amide) 5-(2-oxo-2H-(1,3')bipyridinyl-6'-yl)-amide" | 19697924 |
| C545880 | 4,5-dihydropyrazole-1,5-dicarboxylic acid 1-((4-chlorophenyl)-amide) 5-(2-oxo-2H-(1,3')bipyridinyl-6'-yl)-amide | "Mephenytoin inhibits the reaction [CYP2C19 protein results in increased metabolism of 4,5-dihydropyrazole-1,5-dicarboxylic acid 1-((4-chlorophenyl)-amide) 5-(2-oxo-2H-(1,3')bipyridinyl-6'-yl)-amide]" | 19697924 |
| C108971 | 4-amino-2-phenoxymethanesulfonanilide | 4-amino-2-phenoxymethanesulfonanilide inhibits the reaction [CYP2C19 protein results in increased oxidation of Mephenytoin] | 19053182 |
| C108971 | 4-amino-2-phenoxymethanesulfonanilide | CYP2C19 protein results in increased oxidation of 4-amino-2-phenoxymethanesulfonanilide | 19053182 |
| C108971 | 4-amino-2-phenoxymethanesulfonanilide | furafylline inhibits the reaction [CYP2C19 protein results in increased oxidation of 4-amino-2-phenoxymethanesulfonanilide] | 19053182 |
| C108971 | 4-amino-2-phenoxymethanesulfonanilide | Quinidine affects the reaction [CYP2C19 protein results in increased oxidation of 4-amino-2-phenoxymethanesulfonanilide] | 19053182 |
| C108971 | 4-amino-2-phenoxymethanesulfonanilide | Ticlopidine inhibits the reaction [CYP2C19 protein results in increased oxidation of 4-amino-2-phenoxymethanesulfonanilide] | 19053182 |
| C075205 | 4-bromo-2-chlorophenol | [CYP2C19 protein results in increased metabolism of profenofos] which results in increased abundance of 4-bromo-2-chlorophenol | 23415833 |
| C025687 | 4-hydroxymephenytoin | CYP2C19 protein results in increased chemical synthesis of 4-hydroxymephenytoin | 12401345|1515555 |
| C025687 | 4-hydroxymephenytoin | [CYP2C19 protein results in increased metabolism of Mephenytoin] which results in increased chemical synthesis of 4-hydroxymephenytoin | 25084468 |
| C001470 | 4-ipomeanol | CYP2C19 protein results in increased activity of 4-ipomeanol | 15892579 |
| C044390 | 4-(methylsulfinyl)phenol | CYP2C19 protein results in increased abundance of 4-(methylsulfinyl)phenol analog | 27665777 |
| C044390 | 4-(methylsulfinyl)phenol | "[CYP2C19 protein results in increased oxidation of 3,5-xylenol analog] which results in increased abundance of 4-(methylsulfinyl)phenol analog" | 27665777 |
| C024836 | 4-nitrophenol | CYP2C19 protein results in increased hydroxylation of 4-nitrophenol | 15135088 |
| C016583 | 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone | CYP2C19 protein affects the metabolism of and results in increased activity of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone | 11774366 |
| C105260 | 4-tert-octylphenol | CYP2C19 gene SNP results in increased susceptibility to 4-tert-octylphenol | 23555028 |
| C502236 | 5-(4-(3-(4-cyclohexyl-2-propylphenoxy)propoxy)phenyl)-1,3-oxazolidine-2,4-dione | "CYP2C19 protein results in increased hydroxylation of 5-(4-(3-(4-cyclohexyl-2-propylphenoxy)propoxy)phenyl)-1,3-oxazolidine-2,4-dione" | 15708677 |
| C040997 | 5-bromotryptamine | 5-bromotryptamine analog results in decreased activity of CYP2C19 protein | 26599973 |
| C040997 | 5-bromotryptamine | [5-bromotryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole | 26599973 |
| C529169 | 5-chlorotryptamine | 5-chlorotryptamine analog results in decreased activity of CYP2C19 protein | 26599973 |
| C529169 | 5-chlorotryptamine | [5-chlorotryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole | 26599973 |
| C051101 | 5-fluoro-alpha-methyltryptamine | 5-fluoro-alpha-methyltryptamine analog results in decreased activity of CYP2C19 protein | 26599973 |
| C051101 | 5-fluoro-alpha-methyltryptamine | [5-fluoro-alpha-methyltryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole | 26599973 |
| C034536 | 5-fluorotryptamine | 5-fluorotryptamine analog results in decreased activity of CYP2C19 protein | 26599973 |
| C034536 | 5-fluorotryptamine | [5-fluorotryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole | 26599973 |
| C117715 | 5-hydroxydiclofenac | [CYP2C19 protein co-treated with GSTP1 protein co-treated with Glutathione] results in increased abundance of 5-hydroxydiclofenac | 24246759 |
| C544471 | 5-hydroxythalidomide | CYP2C19 protein results in increased abundance of 5-hydroxythalidomide | 24350712 |
| C544471 | 5-hydroxythalidomide | [CYP2C19 protein results in increased hydroxylation of Thalidomide] which results in increased chemical synthesis of 5-hydroxythalidomide | 20443640 |
| C544471 | 5-hydroxythalidomide | [CYP2C19 protein results in increased oxidation of Thalidomide] which results in increased abundance of 5-hydroxythalidomide | 24350712 |
| C452282 | 5'-hydroxythalidomide | CYP2C19 protein results in increased abundance of 5'-hydroxythalidomide | 24350712 |
| C452282 | 5'-hydroxythalidomide | [CYP2C19 protein results in increased hydroxylation of Thalidomide] which results in increased chemical synthesis of 5'-hydroxythalidomide | 20443640 |
| C452282 | 5'-hydroxythalidomide | [CYP2C19 protein results in increased oxidation of Thalidomide] which results in increased abundance of 5'-hydroxythalidomide | 24350712 |
| C033696 | 5-methoxy-N,N-diisopropyltryptamine | "5-methoxy-N,N-diisopropyltryptamine analog results in decreased activity of CYP2C19 protein" | 26599973 |
| C033696 | 5-methoxy-N,N-diisopropyltryptamine | "[5-methoxy-N,N-diisopropyltryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole" | 26599973 |
| C027552 | 5-methyltryptamine | 5-methyltryptamine analog results in decreased activity of CYP2C19 protein | 26599973 |
| C027552 | 5-methyltryptamine | [5-methyltryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole | 26599973 |
| C000588958 | 5-(N-(4-((4-ethylbenzyl)thio)phenyl)sulfamoyl)-2-methylbenzoic acid | 5-(N-(4-((4-ethylbenzyl)thio)phenyl)sulfamoyl)-2-methylbenzoic acid results in decreased activity of CYP2C19 protein | 23631744 |
| C547858 | 5-n-butyl-pyrazolo(1,5-a)pyrimidine | "5-n-butyl-pyrazolo(1,5-a)pyrimidine metabolite binds to CYP2C19 protein" | 19928966 |
| C107882 | 7,8-dihydromethysticin | "7,8-dihydromethysticin results in decreased activity of CYP2C19 protein" | 16033948 |
| C056033 | 7-ethoxy-4-trifluoromethylcoumarin | CYP2C19 protein results in decreased ethylation of 7-ethoxy-4-trifluoromethylcoumarin | 9241656 |
| C084236 | 7-hydroxy-4-trifluoromethylcoumarin | CYP2C19 protein results in increased chemical synthesis of 7-hydroxy-4-trifluoromethylcoumarin | 9241656 |
| C036696 | 7-methyltryptamine | 7-methyltryptamine analog results in decreased activity of CYP2C19 protein | 26599973 |
| C036696 | 7-methyltryptamine | [7-methyltryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole | 26599973 |
| D000074 | Acenocoumarol | CYP2C19 protein affects the metabolism of Acenocoumarol | 11918509 |
| D000082 | Acetaminophen | Acetaminophen results in decreased expression of CYP2C19 mRNA | 29067470 |
| D000111 | Acetylcysteine | [CYP2C19 protein co-treated with Acetylcysteine] results in increased metabolism of Emodin metabolite | 27989148 |
| D000157 | Aconitine | [Omeprazole results in decreased activity of CYP2C19 protein] which results in decreased chemical synthesis of Aconitine metabolite | 21277363 |
| D000244 | Adenosine Diphosphate | CYP2C19 gene affects the susceptibility to [Adenosine Diphosphate co-treated with clopidogrel] | 16772608 |
| D000244 | Adenosine Diphosphate | CYP2C19 gene SNP affects the reaction [Adenosine Diphosphate results in increased expression of SELP protein] | 18394438 |
| D000244 | Adenosine Diphosphate | CYP2C19 gene SNP affects the susceptibility to [Adenosine Diphosphate co-treated with Arachidonic Acid] | 18004210 |
| C039668 | adinazolam | CYP2C19 protein results in decreased methylation of adinazolam | 9600717 |
| C039668 | adinazolam | Omeprazole inhibits the reaction [CYP2C19 protein results in decreased methylation of adinazolam] | 9600717 |
| C016601 | afimoxifene | CYP2C19 protein results in increased metabolism of afimoxifene | 29285606 |
| D016604 | Aflatoxin B1 | Aflatoxin B1 affects the expression of CYP2C19 protein | 20106945 |
| D016604 | Aflatoxin B1 | Aflatoxin B1 results in decreased expression of CYP2C19 mRNA | 22100608|2715375 |
| D016604 | Aflatoxin B1 | Aflatoxin B1 results in decreased methylation of CYP2C19 gene | 27153756 |
| D016604 | Aflatoxin B1 | [CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Aflatoxin B1 | 23397584 |
| D000447 | Aldehydes | Aldehydes results in decreased expression of CYP2C19 mRNA | 25014914 |
| C409045 | almotriptan | CYP2C19 protein results in decreased methylation of almotriptan | 12642466 |
| D017962 | alpha-Linolenic Acid | alpha-Linolenic Acid results in decreased activity of CYP2C19 protein | 16978661 |
| D017962 | alpha-Linolenic Acid | CYP2C19 protein results in increased metabolism of [alpha-Linolenic Acid co-treated with NADP] | 16978661 |
| D000638 | Amiodarone | CYP2C19 protein results in decreased susceptibility to Amiodarone | 26477383 |
| D000639 | Amitriptyline | [CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Amitriptyline | 23397584 |
| D000639 | Amitriptyline | CYP2C19 protein results in increased metabolism of Amitriptyline | 27320963 |
| C006566 | amitriptyline N-oxide | CYP2C19 protein results in increased abundance of amitriptyline N-oxide | 27320963 |
| D000655 | Amodiaquine | Amodiaquine results in decreased activity of CYP2C19 protein | 11124226 |
| D016718 | Arachidonic Acid | Arachidonic Acid results in decreased activity of CYP2C19 protein | 16978661 |
| D016718 | Arachidonic Acid | CYP2C19 gene SNP affects the susceptibility to [Adenosine Diphosphate co-treated with Arachidonic Acid] | 18004210 |
| D016718 | Arachidonic Acid | CYP2C19 protein results in increased metabolism of Arachidonic Acid | 12675279 |
| D016718 | Arachidonic Acid | CYP2C19 protein results in increased metabolism of [Arachidonic Acid co-treated with NADP] | 16978661 |
| D001095 | Arachidonic Acids | CYP2C19 protein results in increased chemical synthesis of Arachidonic Acids metabolite | 12675279 |
| C031327 | artemisinine | artemisinine results in decreased activity of CYP2C19 protein | 11124226 |
| C004446 | asiaticoside | asiaticoside results in decreased activity of CYP2C19 protein | 21349323 |
| D001280 | Atrazine | [CYP1A1 protein co-treated with CYP2B6 protein co-treated with CYP2C19 protein] results in decreased susceptibility to Atrazine | 16608219 |
| D001280 | Atrazine | [CYP1A1 protein co-treated with CYP2B6 protein co-treated with CYP2C19 protein] results in decreased susceptibility to [norflurazone co-treated with metolachlor co-treated with Atrazine] | 16608219 |
| C423185 | avasimibe | avasimibe results in decreased activity of CYP2C19 protein | 15333513 |
| C096128 | benfuracarb | CYP2C19 protein results in increased oxidation of benfuracarb | 24016712 |
| C061004 | benidipine | benidipine results in decreased activity of CYP2C19 protein | 10805063 |
| D001553 | Benzbromarone | Benzbromarone analog binds to and results in decreased activity of CYP2C19 protein | 15615526 |
| D001553 | Benzbromarone | Benzbromarone binds to and results in decreased activity of CYP2C19 protein | 15615526 |
| D001553 | Benzbromarone | CYP2C19 protein results in increased metabolism of Benzbromarone | 21449597 |
| D019324 | beta-Naphthoflavone | beta-Naphthoflavone results in decreased expression of CYP2C19 mRNA | 16985168 |
| D001564 | Benzo(a)pyrene | "[Benzo(a)pyrene co-treated with dibenzo(a,l)pyrene] results in increased expression of CYP2C19 mRNA" | 17690111 |
| D004958 | Estradiol | CYP2C19 protein results in increased chemical synthesis of Estradiol | 9714305 |
| C006780 | bisphenol A | bisphenol A results in decreased activity of CYP2C19 protein | 10784435 |
| C006780 | bisphenol A | CYP2C19 protein results in increased glutathionylation of bisphenol A | 23470418 |
| C006780 | bisphenol A | CYP2C19 protein results in increased glutathionylation of bisphenol A metabolite | 23470418 |
| C006780 | bisphenol A | CYP2C19 protein results in increased hydroxylation of bisphenol A | 23470418 |
| C006780 | bisphenol A | CYP2C19 protein results in increased hydroxylation of bisphenol A metabolite | 23470418 |
| C006780 | bisphenol A | bisphenol A results in decreased expression of CYP2C19 mRNA | 25181051 |
| D000069286 | Bortezomib | CYP2C19 protein affects the metabolism of Bortezomib | 15764713 |
| C010831 | bufuralol | CYP2C19 protein results in increased hydroxylation of bufuralol | 9429232 |
| D016642 | Bupropion | CYP2C19 gene polymorphism affects the metabolism of and affects the abundance of Bupropion | 25187485 |
| D002185 | Cannabidiol | Cannabidiol results in decreased activity of CYP2C19 protein | 24667653 |
| D002211 | Capsaicin | Capsaicin results in decreased activity of CYP2C19 protein | 22375877 |
| D002220 | Carbamazepine | Carbamazepine results in increased expression of CYP2C19 mRNA | 17112801 |
| D002220 | Carbamazepine | [CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Carbamazepine | 23397584 |
| D002235 | Carbofuran | CYP2C19 protein results in increased hydroxylation of Carbofuran | 15560889 |
| D002328 | Carisoprodol | [CYP2C19 gene polymorphism affects the metabolism of Carisoprodol] which affects the chemical synthesis of Meprobamate | 12835613 |
| D002328 | Carisoprodol | [CYP2C19 protein results in increased metabolism of Carisoprodol] which results in increased chemical synthesis of Meprobamate | 22527345 |
| C088453 | Celsior | Celsior results in decreased activity of CYP2C19 protein | 15448115 |
| C088453 | Celsior | Celsior results in decreased expression of CYP2C19 mRNA | 15448115 |
| D002701 | Chloramphenicol | Chloramphenicol results in decreased activity of CYP2C19 protein | 26599973 |
| D002701 | Chloramphenicol | [Chloramphenicol results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole | 26599973 |
| D020111 | Chlorodiphenyl (54% Chlorine) | Chlorodiphenyl (54% Chlorine) results in increased expression of CYP2C19 mRNA | 17851650 |
| D002746 | Chlorpromazine | Chlorpromazine results in decreased activity of CYP2C19 protein | 15135088 |
| D002746 | Chlorpromazine | [CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Chlorpromazine | 23397584 |
| D002746 | Chlorpromazine | CYP2C19 protein affects the methylation of Chlorpromazine | 20615392 |
| D002746 | Chlorpromazine | CYP2C19 protein results in decreased susceptibility to Chlorpromazine | 26477383 |
| D004390 | Chlorpyrifos | Chlorpyrifos results in increased expression of CYP2C19 mRNA | 16757081 |
| D004390 | Chlorpyrifos | CYP2C19 protein affects the metabolism of Chlorpyrifos | 15764407|1619016 |
| D004390 | Chlorpyrifos | CYP2C19 protein results in decreased activity of Chlorpyrifos | 22281205 |
| D004390 | Chlorpyrifos | CYP2C19 results in increased metabolism of Chlorpyrifos | 20709133 |
| C029010 | cinnamic acid | cinnamic acid analog results in decreased activity of CYP2C19 protein | 15072549 |
| D015283 | Citalopram | CYP2C19 protein polymorphism results in decreased methylation of Citalopram | 12975335 |
| D015283 | Citalopram | CYP2C19 protein results in decreased methylation of Citalopram analog | 9110356 |
| D015283 | Citalopram | CYP2C19 protein affects the metabolism of Citalopram | 16702909 |
| D015283 | Citalopram | CYP2C19 protein affects the methylation of Citalopram | 15765832 |
| C012255 | clobazam | CYP2C19 protein results in increased metabolism of clobazam | 28243904 |
| C012255 | clobazam | [CYP2C19 protein results in increased metabolism of clobazam] which results in increased chemical synthesis of N-desmethylclobazam | 28243904 |
| D002997 | Clomipramine | CYP2C19 protein affects the metabolism of Clomipramine | 10353456 |
| C055162 | clopidogrel | ABCB1 gene affects the reaction [CYP2C19 gene affects the susceptibility to clopidogrel] | 19934793 |
| C055162 | clopidogrel | CYP2C19 gene affects the reaction [clopidogrel affects the phosphorylation of VASP protein] | 16772608 |
| C055162 | clopidogrel | CYP2C19 gene affects the susceptibility to [Adenosine Diphosphate co-treated with clopidogrel] | 16772608 |
| C055162 | clopidogrel | CYP2C19 gene affects the susceptibility to clopidogrel | 18532997|1942991 |
| C055162 | clopidogrel | CYP2C19 gene polymorphism affects the abundance of clopidogrel metabolite | 20217574 |
| C055162 | clopidogrel | CYP2C19 gene polymorphism affects the susceptibility to clopidogrel | 20166430|2018061 |
| C055162 | clopidogrel | CYP2C19 gene polymorphism results in decreased metabolism of and results in decreased activity of clopidogrel | 20180610 |
| C055162 | clopidogrel | CYP2C19 gene polymorphism results in decreased metabolism of clopidogrel | 19106084 |
| C055162 | clopidogrel | CYP2C19 gene polymorphism results in decreased susceptibility to clopidogrel | 19106084 |
| C055162 | clopidogrel | CYP2C19 gene polymorphism results in increased susceptibility to clopidogrel | 20083681 |
| C055162 | clopidogrel | CYP2C19 gene SNP affects the susceptibility to clopidogrel | 17900275 |
| C055162 | clopidogrel | CYP2C19 gene SNP promotes the reaction [CYP2C19 gene SNP affects the susceptibility to clopidogrel] | 19106083 |
| C055162 | clopidogrel | CYP2C19 gene SNP results in decreased metabolism of clopidogrel | 17900275 |
| C055162 | clopidogrel | CYP2C19 gene SNP results in decreased susceptibility to clopidogrel | 17697139|1957632 |
| C055162 | clopidogrel | CYP2C19 gene SNP results in increased susceptibility to clopidogrel | 19496924 |
| C055162 | clopidogrel | CYP2C19 protein results in increased metabolism of and results in increased activity of clopidogrel | 20180610 |
| C055162 | clopidogrel | CYP2C19 protein results in increased metabolism of clopidogrel | 18532997 |
| C055162 | clopidogrel | CYP2C19 protein results in increased oxidation of and results in increased cleavage of clopidogrel metabolite | 19170597 |
| C055162 | clopidogrel | CYP2C19 protein results in increased oxidation of clopidogrel | 19812348 |
| C055162 | clopidogrel | CYP2C9 gene affects the reaction [CYP2C19 gene affects the susceptibility to clopidogrel] | 19926050|1993479 |
| C055162 | clopidogrel | N-3-benzylnirvanol inhibits the reaction [CYP2C19 protein results in increased oxidation of clopidogrel] | 19812348 |
| C055162 | clopidogrel | Omeprazole inhibits the reaction [CYP2C19 protein results in increased oxidation of clopidogrel] | 19812348 |
| C055162 | clopidogrel | P2RY12 gene SNP affects the reaction [CYP2C19 gene SNP affects the susceptibility to clopidogrel] | 18577829 |
| D003024 | Clozapine | [CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Clozapine | 23397584 |
| D003024 | Clozapine | CYP2C19 protein results in increased metabolism of Clozapine | 18809730|2732096 |
| C079149 | clozapine N-oxide | CYP2C19 protein results in increased abundance of clozapine N-oxide | 27320963 |
| C079149 | clozapine N-oxide | CYP2C19 protein results in increased chemical synthesis of clozapine N-oxide | 18809730 |
| D009249 | NADP | [CYP2C19 protein co-treated with NADP] results in increased metabolism of Oxymetazoline | 21177487 |
| D009249 | NADP | CYP2C19 protein results in increased metabolism of [alpha-Linolenic Acid co-treated with NADP] | 16978661 |
| D009249 | NADP | CYP2C19 protein results in increased metabolism of [Arachidonic Acid co-treated with NADP] | 16978661 |
| D009249 | NADP | CYP2C19 protein results in increased metabolism of [Docosahexaenoic Acids co-treated with NADP] | 16978661 |
| D009249 | NADP | CYP2C19 protein results in increased metabolism of [Eicosapentaenoic Acid co-treated with NADP] | 16978661 |
| D009249 | NADP | CYP2C19 protein results in increased metabolism of [Linoleic Acid co-treated with NADP] | 16978661 |
| D009249 | NADP | Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] | 24120545 |
| D009249 | NADP | [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid | 24120545 |
| D009249 | NADP | Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] | 24120545 |
| D009249 | NADP | Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] | 24120545 |
| D009249 | NADP | Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] | 24120545 |
| C007164 | cumene hydroperoxide | CYP2C19 protein affects the oxidation of cumene hydroperoxide | 17478480 |
| D003505 | Cyclodextrins | Cyclodextrins analog results in decreased activity of CYP2C19 protein | 15665498 |
| D003520 | Cyclophosphamide | CYP2C19 gene polymorphism results in decreased metabolism of Cyclophosphamide | 16116487 |
| D003520 | Cyclophosphamide | CYP2C19 protein polymorphism affects the activity of and affects the susceptibility to Cyclophosphamide | 15248218 |
| D003520 | Cyclophosphamide | CYP2C19 protein results in increased metabolism of Cyclophosphamide | 16116487 |
| D003520 | Cyclophosphamide | CYP2C19 results in increased activity of Cyclophosphamide | 9241661 |
| D016572 | Cyclosporine | Cyclosporine results in decreased expression of CYP2C19 mRNA | 20106945 |
| C017160 | cypermethrin | cypermethrin results in increased expression of CYP2C19 mRNA | 22310298 |
| C017180 | decamethrin | decamethrin results in increased expression of CYP2C19 mRNA | 22310298 |
| D003671 | DEET | CYP2C19 protein results in increased metabolism of DEET | 11854147 |
| D003671 | DEET | [fipronil co-treated with DEET] results in decreased expression of CYP2C19 mRNA | 27091632 |
| D020008 | Delavirdine | Delavirdine results in decreased activity of CYP2C19 protein | 11225565 |
| C047386 | desethylamodiaquine | desethylamodiaquine results in decreased activity of CYP2C19 protein | 11124226 |
| D003891 | Desipramine | Desipramine results in decreased activity of CYP2C19 protein | 15135088 |
| D003907 | Dexamethasone | Dexamethasone inhibits the reaction [Freund's Adjuvant results in decreased expression of CYP2C19 mRNA] | 21149847 |
| D036381 | Diarylheptanoids | Diarylheptanoids results in decreased activity of CYP2C19 protein | 23850985 |
| D003975 | Diazepam | CYP2C19 protein affects the metabolism of Diazepam | 15801540 |
| D003975 | Diazepam | CYP2C19 protein affects the metabolism of Diazepam | 15286053|1580154 |
| D003975 | Diazepam | CYP2C19 protein results in increased metabolism of Diazepam | 12464242 |
| D003975 | Diazepam | CYP2C19 protein affects the metabolism of Diazepam | 15801540 |
| D003976 | Diazinon | CYP2C19 protein affects the metabolism of Diazinon | 15764407 |
| D003976 | Diazinon | CYP2C19 protein results in decreased sulfation of and results in increased activity of Diazinon | 15764407 |
| D003976 | Diazinon | CYP2C19 protein results in increased metabolism of and results in increased activity of Diazinon | 11708902 |
| D003976 | Diazinon | Diazinon results in increased expression of CYP2C19 mRNA | 16757081 |
| C041517 | dibenzo(a,l)pyrene | "[Benzo(a)pyrene co-treated with dibenzo(a,l)pyrene] results in increased expression of CYP2C19 mRNA" | 17690111 |
| C558664 | dibenzylfluorescein | CYP2C19 protein results in increased metabolism of dibenzylfluorescein | 23850985 |
| C558664 | dibenzylfluorescein | [CYP2C19 protein results in increased metabolism of dibenzylfluorescein] which results in increased chemical synthesis of Fluorescein | 23850985 |
| C558664 | dibenzylfluorescein | Tranylcypromine inhibits the reaction [[CYP2C19 protein results in increased metabolism of dibenzylfluorescein] which results in increased chemical synthesis of Fluorescein] | 23850985 |
| D004008 | Diclofenac | CYP2C19 protein results in increased hydroxylation of Diclofenac | 15677349 |
| D004008 | Diclofenac | [CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Diclofenac | 23397584 |
| D004008 | Diclofenac | [CYP2C19 protein co-treated with CYP2C9 protein] results in increased hydroxylation of Diclofenac | 15486075 |
| D004008 | Diclofenac | CYP2C19 protein results in increased hydroxylation of Diclofenac | 18511451 |
| D004008 | Diclofenac | CYP2C19 protein results in increased susceptibility to Diclofenac | 28762043 |
| D004049 | Diethylcarbamazine | Diethylcarbamazine results in increased activity of CYP2C19 protein | 11124226 |
| C039060 | dihydroartemisinin | dihydroartemisinin results in decreased activity of CYP2C19 protein | 11124226 |
| C012906 | dihydrocapsaicin | dihydrocapsaicin results in decreased activity of CYP2C19 protein | 22375877 |
| D002117 | Calcitriol | Calcitriol results in increased expression of CYP2C19 mRNA | 27107558 |
| C012621 | dimemorfan | CYP2C19 protein results in increased oxidation of dimemorfan | 19593786 |
| D004130 | N,N-Dimethyltryptamine | "CYP2C19 protein results in increased metabolism of N,N-Dimethyltryptamine" | 27320963 |
| C049346 | diniconazole | diniconazole affects the activity of CYP2C19 protein | 23611293 |
| C039602 | diosmetin | diosmetin results in decreased activity of CYP2C19 protein | 28867436 |
| D004050 | Ditiocarb | Ditiocarb results in decreased activity of CYP2C19 protein | 8819299 |
| D004281 | Docosahexaenoic Acids | CYP2C19 protein results in increased metabolism of [Docosahexaenoic Acids co-treated with NADP] | 16978661 |
| D004281 | Docosahexaenoic Acids | Docosahexaenoic Acids results in decreased activity of CYP2C19 protein | 16978661 |
| C098320 | efavirenz | efavirenz results in decreased activity of CYP2C19 protein | 11225565 |
| D015118 | Eicosapentaenoic Acid | CYP2C19 protein results in increased metabolism of [Eicosapentaenoic Acid co-treated with NADP] | 16978661 |
| D015118 | Eicosapentaenoic Acid | Eicosapentaenoic Acid results in decreased activity of CYP2C19 protein | 16978661 |
| C034192 | ellipticine | CYP2C19 protein results in increased metabolism of ellipticine | 22917556 |
| D004642 | Emodin | [CYP2C19 protein co-treated with Acetylcysteine] results in increased metabolism of Emodin metabolite | 27989148 |
| D004642 | Emodin | CYP2C19 protein results in increased oxidation of Emodin | 27989148 |
| C105196 | enfuvirtide | enfuvirtide affects the activity of CYP2C19 protein | 15656696 |
| C025004 | estradiol-17 beta-3-methyl ether | CYP2C19 protein results in decreased methylation of estradiol-17 beta-3-methyl ether | 9714305 |
| D004977 | Ethambutol | Ethambutol results in decreased activity of CYP2C19 protein | 24910189 |
| D004997 | Ethinyl Estradiol | CYP2C19 protein results in increased hydroxylation of Ethinyl Estradiol | 15304426 |
| D004997 | Ethinyl Estradiol | [Ethinyl Estradiol co-treated with norgestimate] results in decreased activity of CYP2C19 protein | 16291717 |
| C103110 | eupatorin | eupatorin results in decreased activity of CYP2C19 protein | 21093571 |
| D015738 | Famotidine | Famotidine inhibits the reaction [CYP2C19 gene affects the susceptibility to Lansoprazole] | 15963082 |
| D011345 | Fenofibrate | Fenofibrate results in increased expression of CYP2C19 mRNA | 25572481 |
| C017690 | fenvalerate | fenvalerate results in increased expression of CYP2C19 mRNA | 22310298 |
| C082360 | fipronil | [fipronil co-treated with DEET] results in decreased expression of CYP2C19 mRNA | 27091632 |
| D015725 | Fluconazole | CYP2C19 protein results in increased metabolism of Fluconazole | 17702393 |
| D015725 | Fluconazole | Fluconazole results in decreased activity of CYP2C19 protein | 12464242|1584349 |
| D015725 | Fluconazole | [Fluconazole results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole | 26599973 |
| D015725 | Fluconazole | Fluconazole results in decreased activity of CYP2C19 protein | 16556082|1858554 |
| D005445 | Flunitrazepam | CYP2C19 protein results in increased metabolism of Flunitrazepam | 10911933 |
| D019793 | Fluorescein | [CYP2C19 protein results in increased metabolism of dibenzylfluorescein] which results in increased chemical synthesis of Fluorescein | 23850985 |
| D019793 | Fluorescein | Tranylcypromine inhibits the reaction [[CYP2C19 protein results in increased metabolism of dibenzylfluorescein] which results in increased chemical synthesis of Fluorescein] | 23850985 |
| D005473 | Fluoxetine | CYP2C19 gene polymorphism affects the metabolism of Fluoxetine | 11453896|1623614 |
| D005473 | Fluoxetine | CYP2C19 protein affects the metabolism of Fluoxetine | 16236141 |
| D005473 | Fluoxetine | CYP2C19 protein results in increased metabolism of Fluoxetine | 11453896|1175210 |
| D005473 | Fluoxetine | Fluoxetine inhibits the reaction [CYP2C19 protein results in increased hydroxylation of Mephenytoin] | 22652334 |
| D005473 | Fluoxetine | Fluoxetine results in decreased activity of CYP2C19 protein | 22652334 |
| D005473 | Fluoxetine | Omeprazole inhibits the reaction [CYP2C19 protein results in increased metabolism of Fluoxetine] | 11752104 |
| D005476 | Fluphenazine | Fluphenazine results in decreased activity of CYP2C19 protein | 15135088 |
| D005485 | Flutamide | [CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Flutamide | 23397584 |
| D005485 | Flutamide | CYP2C19 protein results in increased susceptibility to Flutamide | 28762043 |
| D005620 | Freund's Adjuvant | Dexamethasone inhibits the reaction [Freund's Adjuvant results in decreased expression of CYP2C19 mRNA] | 21149847 |
| D005620 | Freund's Adjuvant | Freund's Adjuvant results in decreased expression of CYP2C19 mRNA | 21149847 |
| D005620 | Freund's Adjuvant | Prednisolone inhibits the reaction [Freund's Adjuvant results in decreased expression of CYP2C19 mRNA] | 21149847 |
| C050131 | furafylline | furafylline inhibits the reaction [CYP2C19 protein results in increased oxidation of 4-amino-2-phenoxymethanesulfonanilide] | 19053182 |
| C048393 | germacrone | germacrone results in decreased activity of CYP2C19 protein | 23850985 |
| D005947 | Glucose | Glucose results in decreased expression of CYP2C19 mRNA | 23245955 |
| D005978 | Glutathione | [CYP2C19 protein co-treated with GSTP1 protein co-treated with Glutathione] results in increased abundance of 2'-(glutathion-S-yl)-deschlorodiclofenac | 24246759 |
| D005978 | Glutathione | [CYP2C19 protein co-treated with GSTP1 protein co-treated with Glutathione] results in increased abundance of 5-hydroxydiclofenac | 24246759 |
| D006540 | Herbicides | [CYP1A1 protein co-treated with CYP2B6 protein co-treated with CYP2C19 protein] results in decreased susceptibility to Herbicides | 16608219 |
| D006591 | Hexobarbital | CYP2C19 protein results in increased metabolism of Hexobarbital | 12464242 |
| C496216 | hydrobupropion | CYP2C19 gene polymorphism affects the abundance of hydrobupropion | 25187485 |
| C058309 | hypaconitine | CYP2C19 protein results in increased metabolism of hypaconitine | 21550385 |
| D007069 | Ifosfamide | CYP2C19 protein results in increased susceptibility to Ifosfamide | 20507880 |
| D007069 | Ifosfamide | CYP2C19 results in increased activity of Ifosfamide | 9241661 |
| D007099 | Imipramine | CYP2C19 protein affects the metabolism of Imipramine | 15286053 |
| D007099 | Imipramine | CYP2C19 protein results in decreased methylation of and results in increased activity of Imipramine | 15922009 |
| D007099 | Imipramine | Organophosphorus Compounds inhibits the reaction [CYP2C19 protein results in decreased methylation of and results in increased activity of Imipramine] | 15922009 |
| C002921 | imipramine N-oxide | CYP2C19 protein results in increased abundance of imipramine N-oxide | 27320963 |
| D007211 | Indoles | CYP2C19 protein results in increased glutathionylation of Indoles | 22429462 |
| C015293 | indopan | indopan results in decreased activity of CYP2C19 protein | 26599973 |
| C015293 | indopan | [indopan results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole | 26599973 |
| C549713 | isocarbophos | CYP2C19 protein results in increased metabolism of and results in decreased sulfation of and affects the activity of isocarbophos | 24752505 |
| D017964 | Itraconazole | Itraconazole results in decreased activity of CYP2C19 protein | 16556082 |
| D007654 | Ketoconazole | Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] | 24120545 |
| D007654 | Ketoconazole | Ketoconazole results in decreased activity of CYP2C19 protein | 14709627|1561874 |
| D007654 | Ketoconazole | Ketoconazole results in decreased activity of CYP2C19 protein | 16556082 |
| D064747 | Lansoprazole | CYP2C19 affects the reaction [Lansoprazole affects the susceptibility to Tacrolimus] | 15285851 |
| D064747 | Lansoprazole | CYP2C19 affects the susceptibility to [Tacrolimus co-treated with Lansoprazole] | 17377957 |
| D064747 | Lansoprazole | CYP2C19 gene affects the susceptibility to Lansoprazole | 11929404|1596308 |
| D064747 | Lansoprazole | CYP2C19 gene mutant form affects the susceptibility to [Lansoprazole co-treated with Tacrolimus] | 15010519 |
| D064747 | Lansoprazole | CYP2C19 gene polymorphism affects the susceptibility to Lansoprazole | 9272410 |
| D064747 | Lansoprazole | CYP2C19 gene polymorphism results in decreased metabolism of Lansoprazole | 19814645 |
| D064747 | Lansoprazole | CYP2C19 protein affects the metabolism of Lansoprazole | 15010519 |
| D064747 | Lansoprazole | CYP2C19 protein results in increased hydroxylation of Lansoprazole | 11829200|1297533 |
| D064747 | Lansoprazole | CYP2C19 protein results in increased metabolism of Lansoprazole | 8930576 |
| D064747 | Lansoprazole | Famotidine inhibits the reaction [CYP2C19 gene affects the susceptibility to Lansoprazole] | 15963082 |
| D064747 | Lansoprazole | Lansoprazole inhibits the reaction [CYP2C19 protein results in increased hydroxylation of Mephenytoin] | 15258107 |
| D064747 | Lansoprazole | Lansoprazole results in decreased activity of CYP2C19 protein | 21795468 |
| D064747 | Lansoprazole | Lansoprazole results in increased metabolism of CYP2C19 protein | 21212520 |
| D064747 | Lansoprazole | CYP2C19 protein results in increased metabolism of Lansoprazole | 15370958|1981464 |
| D064747 | Lansoprazole | Lansoprazole results in decreased activity of CYP2C19 protein | 11274899|2057563 |
| C011896 | lephetamine | CYP2C19 protein results in decreased alkylation of lephetamine | 26276083 |
| C070840 | licochalcone A | licochalcone A results in decreased activity of CYP2C19 protein | 26100226 |
| C093443 | madecassoside | madecassoside results in decreased activity of CYP2C19 protein | 21349323 |
| D008528 | Mefenamic Acid | CYP2C19 protein results in increased hydroxylation of Mefenamic Acid | 25372302 |
| D008549 | Melarsoprol | Melarsoprol results in decreased activity of CYP2C19 protein | 11124226 |
| D008550 | Melatonin | CYP2C19 protein results in decreased methylation of Melatonin | 15616152 |
| D008550 | Melatonin | CYP2C19 protein results in increased hydroxylation of Melatonin | 15616152 |
| D008617 | Mephenytoin | 4-amino-2-phenoxymethanesulfonanilide inhibits the reaction [CYP2C19 protein results in increased oxidation of Mephenytoin] | 19053182 |
| D008617 | Mephenytoin | CYP2C19 gene SNP affects the hydroxylation of Mephenytoin | 9170147 |
| D008617 | Mephenytoin | CYP2C19 protein affects the hydroxylation of Mephenytoin | 9170147 |
| D008617 | Mephenytoin | CYP2C19 protein affects the metabolism of Mephenytoin | 3577206 |
| D008617 | Mephenytoin | CYP2C19 protein results in increased hydroxylation of Mephenytoin | 12433797|1263724 |
| D008617 | Mephenytoin | CYP2C19 protein results in increased metabolism of Mephenytoin | 11907490|1240134 |
| D008617 | Mephenytoin | [CYP2C19 protein results in increased metabolism of Mephenytoin] which results in increased chemical synthesis of 4-hydroxymephenytoin | 25084468 |
| D008617 | Mephenytoin | CYP2C19 protein results in increased oxidation of Mephenytoin | 17478480|1905318 |
| D008617 | Mephenytoin | Fluoxetine inhibits the reaction [CYP2C19 protein results in increased hydroxylation of Mephenytoin] | 22652334 |
| D008617 | Mephenytoin | GH1 protein inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin] | 11907490 |
| D008617 | Mephenytoin | Lansoprazole inhibits the reaction [CYP2C19 protein results in increased hydroxylation of Mephenytoin] | 15258107 |
| D008617 | Mephenytoin | "Mephenytoin inhibits the reaction [CYP2C19 protein results in increased metabolism of 4,5-dihydropyrazole-1,5-dicarboxylic acid 1-((4-chlorophenyl)-amide) 5-(2-oxo-2H-(1,3')bipyridinyl-6'-yl)-amide]" | 19697924 |
| D008617 | Mephenytoin | Mephenytoin results in decreased activity of CYP2C19 protein | 12467917 |
| D008617 | Mephenytoin | [Mephenytoin results in decreased activity of CYP2C19 protein] which results in decreased degradation of vanoxerine | 11502731 |
| D008617 | Mephenytoin | Omeprazole inhibits the reaction [CYP2C19 protein results in increased hydroxylation of Mephenytoin] | 15258107 |
| D008617 | Mephenytoin | pantoprazole inhibits the reaction [CYP2C19 protein results in increased hydroxylation of Mephenytoin] | 15258107 |
| D008617 | Mephenytoin | perfluorooctane sulfonic acid inhibits the reaction [CYP2C19 protein results in increased oxidation of Mephenytoin] | 21964418 |
| D008617 | Mephenytoin | rabeprazole-thioether inhibits the reaction [CYP2C19 protein results in increased hydroxylation of Mephenytoin] | 15258107 |
| D008617 | Mephenytoin | resveratrol inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin] | 12569440 |
| D008617 | Mephenytoin | sitaxsentan inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin] | 23721565 |
| D008617 | Mephenytoin | Ticlopidine inhibits the reaction [CYP2C19 protein results in increased hydroxylation of Mephenytoin] | 22652334 |
| D008617 | Mephenytoin | Ticlopidine inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin] | 16049126|2385098 |
| D008617 | Mephenytoin | Tranylcypromine inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin] | 12569440|2811916 |
| D008617 | Mephenytoin | ursolic acid inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin] | 15043991 |
| D008617 | Mephenytoin | zafirlukast inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin] | 15370959 |
| D008617 | Mephenytoin | Mephenytoin results in decreased activity of CYP2C19 protein | 19697924 |
| D008618 | Mephobarbital | CYP2C19 protein results in increased metabolism of Mephobarbital | 12464242 |
| C050699 | mepirodipine | mepirodipine results in decreased activity of CYP2C19 protein | 10805063 |
| D008620 | Meprobamate | [CYP2C19 gene polymorphism affects the metabolism of Carisoprodol] which affects the chemical synthesis of Meprobamate | 12835613 |
| D008620 | Meprobamate | [CYP2C19 protein results in increased metabolism of Carisoprodol] which results in increased chemical synthesis of Meprobamate | 22527345 |
| D008714 | Methiocarb | CYP2C19 protein results in increased metabolism of Methiocarb | 27665777 |
| D008714 | Methiocarb | [CYP2C19 protein results in increased metabolism of Methiocarb] which results in increased abundance of methiocarb sulfoxide | 27665777 |
| C097911 | methiocarb sulfoxide | CYP2C19 protein results in increased abundance of methiocarb sulfoxide | 27665777 |
| C097911 | methiocarb sulfoxide | [CYP2C19 protein results in increased metabolism of Methiocarb] which results in increased abundance of methiocarb sulfoxide | 27665777 |
| D003915 | Dextromethorphan | CYP2C19 protein affects the metabolism of Dextromethorphan | 15286053 |
| D008731 | Methoxychlor | [CYP2C19 protein co-treated with CYP2C9 protein] results in decreased methylation of Methoxychlor | 15486075 |
| D008731 | Methoxychlor | CYP2C19 protein results in decreased methylation of Methoxychlor | 12167570|1243379 |
| D008731 | Methoxychlor | CYP2C19 protein results in increased hydroxylation of Methoxychlor | 9714305 |
| D008731 | Methoxychlor | CYP2C19 protein results in increased metabolism of Methoxychlor | 18585438 |
| D018817 | N-Methyl-3,4-methylenedioxyamphetamine | "CYP2C19 affects the metabolism of N-Methyl-3,4-methylenedioxyamphetamine" | 21871945 |
| C076881 | methysticin | methysticin results in decreased activity of CYP2C19 protein | 16033948 |
| C051786 | metolachlor | [CYP1A1 protein co-treated with CYP2B6 protein co-treated with CYP2C19 protein] results in decreased susceptibility to metolachlor | 16608219 |
| C051786 | metolachlor | [CYP1A1 protein co-treated with CYP2B6 protein co-treated with CYP2C19 protein] results in decreased susceptibility to [norflurazone co-treated with metolachlor co-treated with Atrazine] | 16608219 |
| D008825 | Miconazole | Miconazole results in decreased activity of CYP2C19 protein | 21349323 |
| C068880 | miltirone | miltirone results in decreased activity of CYP2C19 protein | 25686904 |
| D020912 | Moclobemide | CYP2C19 protein results in increased metabolism of Moclobemide | 12464242 |
| C479069 | mono(2-ethyl-5-hydroxyhexyl) phthalate | [CYP2C19 protein results in increased metabolism of mono-(2-ethylhexyl)phthalate] which results in increased chemical synthesis of mono(2-ethyl-5-hydroxyhexyl) phthalate | 22186153 |
| C080276 | mono(2-ethyl-5-oxohexyl)phthalate | [CYP2C19 protein results in increased metabolism of mono-(2-ethylhexyl)phthalate] which results in increased chemical synthesis of mono(2-ethyl-5-oxohexyl)phthalate | 22186153 |
| C016599 | mono-(2-ethylhexyl)phthalate | CYP2C19 protein results in increased metabolism of mono-(2-ethylhexyl)phthalate | 22186153 |
| C016599 | mono-(2-ethylhexyl)phthalate | [CYP2C19 protein results in increased metabolism of mono-(2-ethylhexyl)phthalate] which results in increased chemical synthesis of mono(2-ethyl-5-hydroxyhexyl) phthalate | 22186153 |
| C016599 | mono-(2-ethylhexyl)phthalate | [CYP2C19 protein results in increased metabolism of mono-(2-ethylhexyl)phthalate] which results in increased chemical synthesis of mono(2-ethyl-5-oxohexyl)phthalate | 22186153 |
| D016686 | Monocrotaline | CYP2C19 protein results in increased metabolism of and results in increased activity of Monocrotaline | 19818743 |
| C050132 | mono-N-demethyladinazolam | CYP2C19 protein results in decreased methylation of mono-N-demethyladinazolam | 9600717 |
| C534983 | N-(2-amino-3-methyl-n-butyl)-3-((bis-4-fluorophenyl)methoxy)tropane | CYP2C19 protein results in increased metabolism of N-(2-amino-3-methyl-n-butyl)-3-((bis-4-fluorophenyl)methoxy)tropane | 18425847 |
| C454675 | N-3-benzylnirvanol | [N-3-benzylnirvanol results in decreased activity of CYP2C19 protein] which results in decreased oxidation of Propranolol | 19853591 |
| C454675 | N-3-benzylnirvanol | N-3-benzylnirvanol inhibits the reaction [CYP2C19 protein results in increased oxidation of 2-oxo-clopidogrel] | 19812348 |
| C454675 | N-3-benzylnirvanol | N-3-benzylnirvanol inhibits the reaction [CYP2C19 protein results in increased oxidation of clopidogrel] | 19812348 |
| C454675 | N-3-benzylnirvanol | N-3-benzylnirvanol results in decreased activity of CYP2C19 protein | 15155557|1586065 |
| C454675 | N-3-benzylnirvanol | [N-3-benzylnirvanol results in decreased activity of CYP2C19 protein] which results in decreased oxidation of Propranolol | 19853591 |
| C454675 | N-3-benzylnirvanol | N-3-benzylnirvanol results in decreased activity of CYP2C19 protein | 19853591 |
| C454676 | N-3-benzylphenobarbital | N-3-benzylphenobarbital results in decreased activity of CYP2C19 protein | 21336516 |
| C507425 | N-(4-cyano-benzo(b)thiophene-2-carbonyl)guanidine | CYP2C19 protein results in increased hydroxylation of N-(4-cyano-benzo(b)thiophene-2-carbonyl)guanidine | 16857327 |
| C031721 | naphthalene | naphthalene results in increased expression of CYP2C19 mRNA | 20500019 |
| C024581 | N-desmethylclobazam | CYP2C19 protein results in increased chemical synthesis of N-desmethylclobazam | 28243904 |
| C024581 | N-desmethylclobazam | [CYP2C19 protein results in increased metabolism of clobazam] which results in increased chemical synthesis of N-desmethylclobazam | 28243904 |
| C000598690 | N-ethyl-1,2-diphenylethylamine | "CYP2C19 protein results in decreased alkylation of N-ethyl-1,2-diphenylethylamine" | 26276083 |
| C454678 | N-ethyl-3-toluamide | CYP2C19 protein results in increased chemical synthesis of N-ethyl-3-toluamide | 11854147 |
| D009529 | Nicardipine | Nicardipine results in decreased activity of CYP2C19 protein | 10805063|1586389 |
| C012655 | nimesulide | CYP2C19 protein results in increased glutathionylation of nimesulide | 26524229 |
| C000598691 | N-isopropyl-1,2-diphenylethylamine | "CYP2C19 protein results in decreased alkylation of N-isopropyl-1,2-diphenylethylamine" | 26276083 |
| C578955 | N,N-diallyl-5-methoxytryptamine | "N,N-diallyl-5-methoxytryptamine results in decreased activity of CYP2C19 protein" | 26599973 |
| C578955 | N,N-diallyl-5-methoxytryptamine | "[N,N-diallyl-5-methoxytryptamine results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole" | 26599973 |
| C574385 | N,N-didesmethyl-4-hydroxytamoxifen | "CYP2C19 protein results in increased metabolism of N,N-didesmethyl-4-hydroxytamoxifen" | 29285606 |
| C574385 | N,N-didesmethyl-4-hydroxytamoxifen | "[CYP2C19 protein results in increased metabolism of N,N-didesmethyl-4-hydroxytamoxifen] which results in increased abundance of N,N-didesmethyl-4-hydroxytamoxifen" | 29285606 |
| C574385 | N,N-didesmethyl-4-hydroxytamoxifen | "N,N-didesmethyl-4-hydroxytamoxifen results in decreased activity of CYP2C19 protein" | 29285606 |
| C033695 | N,N-diisopropyltryptamine | "N,N-diisopropyltryptamine analog results in decreased activity of CYP2C19 protein" | 26599973 |
| C033695 | N,N-diisopropyltryptamine | "[N,N-diisopropyltryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole" | 26599973 |
| C058272 | norclozapine | CYP2C19 protein results in increased chemical synthesis of norclozapine | 18809730 |
| C008677 | norflurazone | [CYP1A1 protein co-treated with CYP2B6 protein co-treated with CYP2C19 protein] results in decreased susceptibility to norflurazone | 16608219 |
| C008677 | norflurazone | [CYP1A1 protein co-treated with CYP2B6 protein co-treated with CYP2C19 protein] results in decreased susceptibility to [norflurazone co-treated with metolachlor co-treated with Atrazine] | 16608219 |
| C017576 | norgestimate | [Ethinyl Estradiol co-treated with norgestimate] results in decreased activity of CYP2C19 protein | 16291717 |
| D019787 | Linoleic Acid | CYP2C19 protein results in increased metabolism of [Linoleic Acid co-treated with NADP] | 16978661 |
| D019787 | Linoleic Acid | Linoleic Acid results in decreased activity of CYP2C19 protein | 16978661 |
| D009853 | Omeprazole | [5-bromotryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole | 26599973 |
| D009853 | Omeprazole | [5-chlorotryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole | 26599973 |
| D009853 | Omeprazole | [5-fluoro-alpha-methyltryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole | 26599973 |
| D009853 | Omeprazole | [5-fluorotryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole | 26599973 |
| D009853 | Omeprazole | "[5-methoxy-N,N-diisopropyltryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole" | 26599973 |
| D009853 | Omeprazole | [5-methyltryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole | 26599973 |
| D009853 | Omeprazole | [7-methyltryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole | 26599973 |
| D009853 | Omeprazole | [Chloramphenicol results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole | 26599973 |
| D009853 | Omeprazole | CYP2C19 gene alternative form results in decreased metabolism of Omeprazole | 20573087 |
| D009853 | Omeprazole | CYP2C19 protein affects the metabolism of Omeprazole | 14586384|1528605 |
| D009853 | Omeprazole | CYP2C19 protein results in increased hydroxylation of Omeprazole | 12637241|1851145 |
| D009853 | Omeprazole | CYP2C19 protein results in increased metabolism of Omeprazole | 11752104|1246424 |
| D009853 | Omeprazole | [Fluconazole results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole | 26599973 |
| D009853 | Omeprazole | [indopan results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole | 26599973 |
| D009853 | Omeprazole | "[N,N-diallyl-5-methoxytryptamine results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole" | 26599973 |
| D009853 | Omeprazole | "[N,N-diisopropyltryptamine analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole" | 26599973 |
| D009853 | Omeprazole | Omeprazole affects the reaction [CYP2C19 protein affects the metabolism of Warfarin] | 18520598 |
| D009853 | Omeprazole | Omeprazole inhibits the reaction [CYP2C19 protein results in decreased methylation of adinazolam] | 9600717 |
| D009853 | Omeprazole | Omeprazole inhibits the reaction [CYP2C19 protein results in increased hydroxylation of Mephenytoin] | 15258107 |
| D009853 | Omeprazole | Omeprazole inhibits the reaction [CYP2C19 protein results in increased metabolism of Fluoxetine] | 11752104 |
| D009853 | Omeprazole | Omeprazole inhibits the reaction [CYP2C19 protein results in increased oxidation of 2-oxo-clopidogrel] | 19812348 |
| D009853 | Omeprazole | Omeprazole inhibits the reaction [CYP2C19 protein results in increased oxidation of clopidogrel] | 19812348 |
| D009853 | Omeprazole | Omeprazole results in decreased activity of CYP2C19 protein | 15306208|2179546 |
| D009853 | Omeprazole | [Omeprazole results in decreased activity of CYP2C19 protein] which results in decreased chemical synthesis of 16-O-demethylaconitine metabolite | 21277363 |
| D009853 | Omeprazole | [Omeprazole results in decreased activity of CYP2C19 protein] which results in decreased chemical synthesis of Aconitine metabolite | 21277363 |
| D009853 | Omeprazole | [Tryptamines analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole | 26599973 |
| D009853 | Omeprazole | CYP2C19 protein results in increased metabolism of Omeprazole | 11773867 |
| D009943 | Organophosphorus Compounds | Organophosphorus Compounds inhibits the reaction [CYP2C19 protein results in decreased methylation of and results in increased activity of Imipramine] | 15922009 |
| D008939 | Mitotane | Mitotane results in decreased activity of CYP2C19 protein | 25542188 |
| C036006 | oxcarbazepine | oxcarbazepine results in decreased activity of CYP2C19 protein | 12895138|1473106 |
| D010109 | Oxymetazoline | [CYP2C19 protein co-treated with NADP] results in increased metabolism of Oxymetazoline | 21177487 |
| C064276 | pantoprazole | CYP2C19 gene polymorphism affects the susceptibility to pantoprazole | 20223877 |
| C064276 | pantoprazole | CYP2C19 protein results in increased metabolism of pantoprazole | 8930576 |
| C064276 | pantoprazole | pantoprazole inhibits the reaction [CYP2C19 protein results in increased hydroxylation of Mephenytoin] | 15258107 |
| C064276 | pantoprazole | pantoprazole results in decreased activity of CYP2C19 protein | 21795468 |
| D010278 | Parathion | CYP2C19 protein affects the metabolism of Parathion | 12669189|1707935 |
| D010419 | Pentamidine | Pentamidine results in decreased activity of CYP2C19 protein | 11124226 |
| C076994 | perfluorooctane sulfonic acid | perfluorooctane sulfonic acid inhibits the reaction [CYP2C19 protein results in increased oxidation of Mephenytoin] | 21964418 |
| C076994 | perfluorooctane sulfonic acid | perfluorooctane sulfonic acid results in increased expression of CYP2C19 mRNA | 21723365 |
| D026023 | Permethrin | CYP2C19 protein results in increased metabolism of Permethrin | 24548679 |
| D010622 | Phencyclidine | CYP2C19 protein affects the oxidation of Phencyclidine | 16782764 |
| D010622 | Phencyclidine | Phencyclidine results in decreased activity of CYP2C19 protein | 16782764 |
| D010634 | Phenobarbital | CYP2C19 gene polymorphism results in decreased metabolism of Phenobarbital | 16789993 |
| D010634 | Phenobarbital | CYP2C19 protein results in increased metabolism of Phenobarbital | 16789993 |
| D010634 | Phenobarbital | Phenobarbital affects the expression of CYP2C19 mRNA | 19084549 |
| D010634 | Phenobarbital | Phenobarbital results in increased activity of CYP2C19 protein | 19328226 |
| D010634 | Phenobarbital | Phenobarbital results in increased expression of CYP2C19 mRNA | 15629111|1911856 |
| D010672 | Phenytoin | [CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Phenytoin | 23397584 |
| D010672 | Phenytoin | CYP2C19 gene polymorphism results in decreased hydroxylation of Phenytoin | 9860067 |
| D010672 | Phenytoin | CYP2C19 gene polymorphism results in decreased metabolism of Phenytoin | 16789993|9146858 |
| D010672 | Phenytoin | CYP2C19 protein affects the metabolism of Phenytoin | 15855726 |
| D010672 | Phenytoin | CYP2C19 protein results in increased hydroxylation of Phenytoin | 9860067 |
| D010672 | Phenytoin | CYP2C19 protein results in increased metabolism of Phenytoin | 16220110|1678999 |
| D010672 | Phenytoin | CYP2C19 protein results in increased metabolism of Phenytoin | 15569425 |
| C556557 | picoxystrobin | picoxystrobin results in decreased activity of CYP2C19 protein | 23611293 |
| D010936 | Plant Extracts | Plant Extracts results in decreased activity of CYP2C19 protein | 20828605|2109357 |
| D010936 | Plant Extracts | Plant Extracts results in decreased activity of CYP2C19 protein | 16033948 |
| C467566 | pomalidomide | CYP2C19 protein results in increased oxidation of pomalidomide | 24350712 |
| D011223 | Praziquantel | CYP2C19 protein affects the metabolism of Praziquantel | 12920490 |
| D011239 | Prednisolone | Prednisolone inhibits the reaction [Freund's Adjuvant results in decreased expression of CYP2C19 mRNA] | 21149847 |
| C024273 | profenofos | CYP2C19 protein results in increased metabolism of profenofos | 23415833 |
| C024273 | profenofos | [CYP2C19 protein results in increased metabolism of profenofos] which results in increased abundance of 4-bromo-2-chlorophenol | 23415833 |
| D011374 | Progesterone | CYP2C19 protein results in increased hydroxylation of Progesterone | 18957504 |
| D002727 | Proguanil | CYP2C19 protein results in increased metabolism of Proguanil | 12464242 |
| D002727 | Proguanil | Proguanil results in decreased activity of CYP2C19 protein | 11124226 |
| D011433 | Propranolol | CYP2C19 protein results in increased oxidation of Propranolol | 19853591 |
| D011433 | Propranolol | [N-3-benzylnirvanol results in decreased activity of CYP2C19 protein] which results in decreased oxidation of Propranolol | 19853591 |
| D011433 | Propranolol | CYP2C19 protein affects the metabolism of Propranolol | 15286053 |
| D011433 | Propranolol | CYP2C19 protein results in increased oxidation of Propranolol | 19853591 |
| D011433 | Propranolol | CYP2C19 protein results in increased oxidation of Propranolol | 19853591 |
| D011433 | Propranolol | [N-3-benzylnirvanol results in decreased activity of CYP2C19 protein] which results in decreased oxidation of Propranolol | 19853591 |
| D011759 | Pyrrolidines | CYP2C19 protein affects the metabolism of Pyrrolidines | 21053377 |
| D011794 | Quercetin | Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] | 24120545 |
| D011802 | Quinidine | Quinidine affects the reaction [CYP2C19 protein results in increased oxidation of 4-amino-2-phenoxymethanesulfonanilide] | 19053182 |
| D011803 | Quinine | Quinine results in decreased activity of CYP2C19 protein | 11124226 |
| D064750 | Rabeprazole | CYP2C19 affects the susceptibility to [Tacrolimus co-treated with Rabeprazole] | 17377957 |
| D064750 | Rabeprazole | CYP2C19 gene affects the susceptibility to Rabeprazole | 15903128 |
| C523099 | rabeprazole-thioether | rabeprazole-thioether inhibits the reaction [CYP2C19 protein results in increased hydroxylation of Mephenytoin] | 15258107 |
| C059514 | resveratrol | resveratrol inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin] | 12569440 |
| C059514 | resveratrol | resveratrol results in decreased activity of CYP2C19 protein | 12569440 |
| C003300 | retrorsine | CYP2C19 protein results in increased metabolism of and results in increased activity of retrorsine | 19818743 |
| C003300 | retrorsine | CYP2C19 protein results in increased metabolism of retrorsine | 24799337 |
| D012293 | Rifampin | Rifampin results in increased activity of CYP2C19 protein | 22126990 |
| D012293 | Rifampin | Rifampin results in increased expression of and results in increased activity of CYP2C19 protein | 14709624 |
| D012293 | Rifampin | Rifampin results in increased expression of CYP2C19 mRNA | 15629111|1795452 |
| D012293 | Rifampin | Rifampin results in increased expression of CYP2C19 protein | 12584154 |
| D019438 | Ritonavir | Ritonavir results in increased expression of CYP2C19 mRNA | 11918509 |
| C528662 | Salvia extract | Salvia extract results in decreased activity of CYP2C19 protein | 25686904 |
| D020280 | Sertraline | CYP2C19 gene polymorphism affects the metabolism of Sertraline | 11452243 |
| D020280 | Sertraline | CYP2C19 protein results in decreased amination of and results in increased metabolism of Sertraline | 15547048 |
| D020280 | Sertraline | CYP2C19 protein results in decreased methylation of and results in increased metabolism of Sertraline | 15547048 |
| D020280 | Sertraline | CYP2C19 protein results in decreased methylation of Sertraline | 11452243 |
| D020280 | Sertraline | CYP2C19 protein results in increased metabolism of Sertraline | 11452243 |
| C058254 | sibutramine | sibutramine results in decreased activity of CYP2C19 protein | 23777987 |
| C106276 | sitaxsentan | sitaxsentan inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin] | 23721565 |
| C021092 | stiripentol | stiripentol results in decreased activity of CYP2C19 protein | 16022579 |
| D013498 | Suramin | Suramin results in decreased activity of CYP2C19 protein | 11124226 |
| D016559 | Tacrolimus | CYP2C19 affects the reaction [Lansoprazole affects the susceptibility to Tacrolimus] | 15285851 |
| D016559 | Tacrolimus | CYP2C19 affects the susceptibility to [Tacrolimus co-treated with Lansoprazole] | 17377957 |
| D016559 | Tacrolimus | CYP2C19 affects the susceptibility to [Tacrolimus co-treated with Rabeprazole] | 17377957 |
| D016559 | Tacrolimus | CYP2C19 gene mutant form affects the susceptibility to [Lansoprazole co-treated with Tacrolimus] | 15010519 |
| D013629 | Tamoxifen | [CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Tamoxifen | 23397584 |
| D013629 | Tamoxifen | CYP2C19 gene polymorphism results in increased susceptibility to Tamoxifen | 21047200 |
| D013629 | Tamoxifen | CYP2C19 protein results in increased metabolism of Tamoxifen | 29285606 |
| D013629 | Tamoxifen | "[CYP2C19 protein results in increased metabolism of Tamoxifen] which results in increased abundance of 1-(4-hydroxyphenyl)-1,2-diphenyl-1-butene" | 29285606 |
| D013629 | Tamoxifen | Tamoxifen metabolite results in increased activity of CYP2C19 protein | 29285606 |
| C021751 | tanshinone | tanshinone results in decreased activity of CYP2C19 protein | 25686904 |
| D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin affects the expression of CYP2C19 mRNA | 22298810 |
| D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin results in decreased expression of CYP2C19 mRNA | 16985168 |
| D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin results in increased expression of CYP2C19 mRNA | 20106945 |
| C524826 | tetraconazole | tetraconazole affects the activity of CYP2C19 protein | 23611293 |
| D013792 | Thalidomide | CYP2C19 protein results in increased hydroxylation of Thalidomide | 20443640 |
| D013792 | Thalidomide | [CYP2C19 protein results in increased hydroxylation of Thalidomide] which results in increased chemical synthesis of 5-hydroxythalidomide | 20443640 |
| D013792 | Thalidomide | [CYP2C19 protein results in increased hydroxylation of Thalidomide] which results in increased chemical synthesis of 5'-hydroxythalidomide | 20443640 |
| D013792 | Thalidomide | CYP2C19 protein results in increased oxidation of Thalidomide | 24350712 |
| D013792 | Thalidomide | [CYP2C19 protein results in increased oxidation of Thalidomide] which results in increased abundance of 5-hydroxythalidomide | 24350712 |
| D013792 | Thalidomide | [CYP2C19 protein results in increased oxidation of Thalidomide] which results in increased abundance of 5'-hydroxythalidomide | 24350712 |
| D008063 | Thioctic Acid | Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] | 24120545 |
| D013881 | Thioridazine | [CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Thioridazine | 23397584 |
| D013881 | Thioridazine | Thioridazine results in decreased activity of CYP2C19 protein | 15135088 |
| D013988 | Ticlopidine | CYP2C19 protein results in increased oxidation of and results in increased cleavage of Ticlopidine metabolite | 19170597 |
| D013988 | Ticlopidine | Ticlopidine inhibits the reaction [CYP2C19 protein results in increased hydroxylation of Mephenytoin] | 22652334 |
| D013988 | Ticlopidine | Ticlopidine inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin] | 16049126|2385098 |
| D013988 | Ticlopidine | Ticlopidine inhibits the reaction [CYP2C19 protein results in increased oxidation of 4-amino-2-phenoxymethanesulfonanilide] | 19053182 |
| D013988 | Ticlopidine | Ticlopidine results in decreased activity of CYP2C19 protein | 10759690|1533351 |
| D013988 | Ticlopidine | Ticlopidine results in decreased activity of CYP2C19 | 19053182 |
| D014044 | Tolbutamide | CYP2C19 protein results in increased metabolism of Tolbutamide | 18511451 |
| C507866 | trans-1,2-dihydro-1,2-naphthalenediol | "CYP2C19 protein results in increased abundance of trans-1,2-dihydro-1,2-naphthalenediol" | 16243959 |
| D014191 | Tranylcypromine | Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid] | 24120545 |
| D014191 | Tranylcypromine | Tranylcypromine inhibits the reaction [[CYP2C19 protein results in increased metabolism of dibenzylfluorescein] which results in increased chemical synthesis of Fluorescein] | 23850985 |
| D014191 | Tranylcypromine | Tranylcypromine inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin] | 12569440|2811916 |
| D014191 | Tranylcypromine | Tranylcypromine results in decreased activity of CYP2C19 protein | 15306208|2385098 |
| D014212 | Tretinoin | Tretinoin results in decreased expression of CYP2C19 mRNA | 16985168 |
| C057693 | troglitazone | [CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to troglitazone | 23397584 |
| C057693 | troglitazone | CYP2C19 gene polymorphism results in increased susceptibility to troglitazone | 12963435 |
| C057693 | troglitazone | CYP2C19 protein results in increased metabolism of troglitazone | 19356091 |
| C057693 | troglitazone | troglitazone results in decreased activity of CYP2C19 protein | 12642470 |
| C057693 | troglitazone | troglitazone results in increased expression of CYP2C19 mRNA | 25572481 |
| D014363 | Tryptamines | Tryptamines analog results in decreased activity of CYP2C19 protein | 26599973 |
| D014363 | Tryptamines | [Tryptamines analog results in decreased activity of CYP2C19 protein] which results in decreased metabolism of Omeprazole | 26599973 |
| C005466 | ursolic acid | ursolic acid inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin] | 15043991 |
| C005466 | ursolic acid | ursolic acid results in decreased activity of CYP2C19 protein | 15043991 |
| D014635 | Valproic Acid | CYP2C19 protein results in increased susceptibility to Valproic Acid | 28762043 |
| D014635 | Valproic Acid | Valproic Acid results in decreased expression of CYP2C19 mRNA | 29154799 |
| D014635 | Valproic Acid | Valproic Acid results in decreased methylation of CYP2C19 gene | 29154799 |
| D014635 | Valproic Acid | Valproic Acid results in increased expression of CYP2C19 mRNA | 25084468 |
| C043425 | vanoxerine | [Mephenytoin results in decreased activity of CYP2C19 protein] which results in decreased degradation of vanoxerine | 11502731 |
| C521013 | veliparib | CYP2C19 protein results in increased metabolism of veliparib | 21436403 |
| D000069470 | Venlafaxine Hydrochloride | CYP2C19 gene polymorphism affects the methylation of Venlafaxine Hydrochloride | 10877013 |
| D000069470 | Venlafaxine Hydrochloride | CYP2C19 protein results in decreased methylation of Venlafaxine Hydrochloride | 10877013 |
| D065819 | Voriconazole | CYP2C19 protein affects the metabolism of Voriconazole | 15914520 |
| D065819 | Voriconazole | Voriconazole results in decreased activity of CYP2C19 protein | 15328084|1591452 |
| D065819 | Voriconazole | Voriconazole results in decreased activity of CYP2C19 protein | 16556082 |
| C574123 | walrycin A | walrycin A results in increased expression of CYP2C19 mRNA | 22314385 |
| D014859 | Warfarin | CYP2C19 gene polymorphism affects the metabolism of and affects the susceptibility to Warfarin | 25652102 |
| D014859 | Warfarin | CYP2C19 gene polymorphism affects the susceptibility to Warfarin | 19752777 |
| D014859 | Warfarin | CYP2C19 polymorphism affects the susceptibility to Warfarin | 27356304 |
| D014859 | Warfarin | CYP2C19 protein affects the metabolism of Warfarin | 18520598 |
| D014859 | Warfarin | CYP2C19 protein affects the susceptibility to Warfarin | 19752777 |
| D014859 | Warfarin | Omeprazole affects the reaction [CYP2C19 protein affects the metabolism of Warfarin] | 18520598 |
| D014859 | Warfarin | CYP2C19 protein polymorphism affects the susceptibility to Warfarin | 25036290 |
| C062735 | zafirlukast | zafirlukast inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin] | 15370959 |
| C062735 | zafirlukast | zafirlukast results in decreased activity of CYP2C19 protein | 15370959 |